Please login to the form below

Not currently logged in
Email:
Password:

Pharma applauds NHS R&D reforms

The pharmaceutical industry welcomes the UK government's new health research strategy, "Best Research for Best Health"

According to a report in the Financial Times (FT), the pharmaceutical industry has welcomed the UK government's new health research strategy, "Best Research for Best Health"

Professor Sally Davies, who is director of NHS R&D, drafted the new strategy. In an interview with FT, she said that the strategy combined spending to improve infrastructure with administrative changes, which would make UK hospitals more attractive to the pharmaceutical industry.

The new strategy will replace multiple research contracts with a single contract, which will reduce pharmaceutical company negotiation times with individual hospital trusts. Davies also revealed a unified "adoption committee" which will decide within two weeks if a proposal should be carried out in the NHS.

Approximately 61 industry-sponsored trials have already been agreed by the government's new clinical research networks and include investigations into cancer, brain disease, mental health, stroke, diabetes, paediatric medicines and primary care. Around 200 more are currently being discussed or assessed, with 91 companies presently involved under the new arrangements.

Both the Association of the British Pharmaceutical Industry and the BioIndustry Association have said they support the new measures. John Patterson, R&D director of AstraZeneca (AZ), who used to be a fierce critic of NHS clinical trial facilities, added that the new strategy had turned the unsatisfactory situation around.

The reforms have also been progressed by GBP 776m (USD 1.6bn) worth of NHS R&D funding in 2007-8, up from GBP 659m in 2006-7. For 2009-10, funding is projected to reach GBP 850m (USD 1.7bn), alongside a transparent mechanism for the way money is distributed based on population size and research excellence.

Total government spending on health research currently exceeds GBP 1.3bn (USD 2.6bn) a year. This includes a GBP 550m (USD 1.1bn) spent by the Medical Research Council (MRC) on biomedical science. A formal co-ordinating mechanism was set up in 2006, with the MRC and NHS working together as the new Office for Strategic Co-ordination of Health Research.

3rd September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....

Infographics